drug

risperidone ODT

Marketedupdated 3mo ago

by Senores Pharmaceuticals Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 24 investigational indications.

indications

investigational

Schizophrenia

all catalysts(0)

nothing on the calendar yet

Trials studying risperidone ODT

phase3Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medicationsrecruitingn=380
phase4An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatmentcompletedn=31
—Long-term Antipsychotic Pediatric Safety Trialcompletedn=509
phase2Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)completedn=499
phase3Long-Term Study of MP-214 in Patients With Schizophreniacompletedn=254
phase3Safety and Efficacy of MP-214 in Patients With Schizophreniacompletedn=512
phase3A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophreniacompletedn=125
—Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapsecompletedn=275

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 26, 2026

37 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (110)

Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
May 31, 2031formulationUS 100585044.8y
May 31, 2031formulationUS 100585044.8y
May 31, 2031formulationUS 100859364.8y
May 31, 2031formulationUS 100859364.8y
May 31, 2031method-of-use (U-3943)US 101829824.8y
May 31, 2031method-of-use (U-3943)US 101829824.8y
May 31, 2031method-of-use (U-3943)US 101951384.8y
May 31, 2031method-of-use (U-3943)US 101951384.8y
May 31, 2031formulationUS 103353664.8y
May 31, 2031formulationUS 103353664.8y
May 31, 2031formulationUS 104636074.8y
May 31, 2031formulationUS 104636074.8y
May 31, 2031formulationUS 108816054.8y
May 31, 2031formulationUS 108816054.8y
May 31, 2031method-of-use (U-3942)US 110071394.8y
May 31, 2031method-of-use (U-3942)US 110071394.8y
May 31, 2031method-of-use (U-3941)US 111731104.8y
May 31, 2031method-of-use (U-3941)US 111731104.8y
May 31, 2031method-of-use (U-3939)US 112413774.8y
May 31, 2031method-of-use (U-3939)US 112413774.8y
May 31, 2031method-of-use (U-3941)US 117520924.8y
May 31, 2031method-of-use (U-3941)US 117520924.8y
May 31, 2031formulationUS 117520934.8y
May 31, 2031formulationUS 117520934.8y
May 31, 2031method-of-use (U-3942)US 117520944.8y
May 31, 2031method-of-use (U-3942)US 117520944.8y
May 31, 2031method-of-use (U-3939)US 117594164.8y
May 31, 2031method-of-use (U-3939)US 117594164.8y
Feb 13, 2028formulationUS 100106121.5y
Feb 13, 2028formulationUS 100106121.5y
Feb 13, 2028method-of-use (U-2608)US 103765901.5y
Feb 13, 2028method-of-use (U-2608)US 103765901.5y
Feb 13, 2028formulationUS 110138091.5y
Feb 13, 2028formulationUS 110138091.5y
Feb 13, 2028method-of-use (U-3135)US 117124751.5y
Feb 13, 2028method-of-use (U-3135)US 117124751.5y
Feb 13, 2028formulationUS 91801971.5y
Feb 13, 2028formulationUS 91801971.5y
Feb 13, 2028method-of-use (U-543)US 91864131.5y
Feb 13, 2028method-of-use (U-543)US 91864131.5y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 5, 2026formulationUS 1111009377d
Nov 5, 2026formulationUS 1111009377d
Sep 26, 2026method-of-use (U-2363)US 1005855437d
Sep 26, 2026method-of-use (U-2363)US 1005855437d
Sep 26, 2026formulationUS 959740237d
Sep 26, 2026formulationUS 959740237d
Jun 26, 2026formulationUS 10406160
Jun 26, 2026formulationUS 10406160

FDA exclusivities (12)

Mar 29, 2027NPNP221d
Mar 29, 2027NPNP221d
May 12, 2026CGTCGT
May 9, 2026CGTCGT
May 9, 2026CGTCGT
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

risperidone ODT

Marketedupdated 3mo ago

by Senores Pharmaceuticals Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 24 investigational indications.

indications

investigational

Schizophrenia

all catalysts(0)

nothing on the calendar yet

Trials studying risperidone ODT

phase3Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medicationsrecruitingn=380
phase4An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatmentcompletedn=31
—Long-term Antipsychotic Pediatric Safety Trialcompletedn=509
phase2Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)completedn=499
phase3Long-Term Study of MP-214 in Patients With Schizophreniacompletedn=254
phase3Safety and Efficacy of MP-214 in Patients With Schizophreniacompletedn=512
phase3A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophreniacompletedn=125
—Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapsecompletedn=275

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 26, 2026

37 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (110)

Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Mar 17, 2042method-of-use (U-4214)US 12329851
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12128132
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Sep 11, 2040formulationUS 12383493
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 5, 2033formulationUS 9023897
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10098882
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 10406161
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 11110094
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9446135
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
Apr 10, 2032formulationUS 9532991
May 31, 2031formulationUS 100585044.8y
May 31, 2031formulationUS 100585044.8y
May 31, 2031formulationUS 100859364.8y
May 31, 2031formulationUS 100859364.8y
May 31, 2031method-of-use (U-3943)US 101829824.8y
May 31, 2031method-of-use (U-3943)US 101829824.8y
May 31, 2031method-of-use (U-3943)US 101951384.8y
May 31, 2031method-of-use (U-3943)US 101951384.8y
May 31, 2031formulationUS 103353664.8y
May 31, 2031formulationUS 103353664.8y
May 31, 2031formulationUS 104636074.8y
May 31, 2031formulationUS 104636074.8y
May 31, 2031formulationUS 108816054.8y
May 31, 2031formulationUS 108816054.8y
May 31, 2031method-of-use (U-3942)US 110071394.8y
May 31, 2031method-of-use (U-3942)US 110071394.8y
May 31, 2031method-of-use (U-3941)US 111731104.8y
May 31, 2031method-of-use (U-3941)US 111731104.8y
May 31, 2031method-of-use (U-3939)US 112413774.8y
May 31, 2031method-of-use (U-3939)US 112413774.8y
May 31, 2031method-of-use (U-3941)US 117520924.8y
May 31, 2031method-of-use (U-3941)US 117520924.8y
May 31, 2031formulationUS 117520934.8y
May 31, 2031formulationUS 117520934.8y
May 31, 2031method-of-use (U-3942)US 117520944.8y
May 31, 2031method-of-use (U-3942)US 117520944.8y
May 31, 2031method-of-use (U-3939)US 117594164.8y
May 31, 2031method-of-use (U-3939)US 117594164.8y
Feb 13, 2028formulationUS 100106121.5y
Feb 13, 2028formulationUS 100106121.5y
Feb 13, 2028method-of-use (U-2608)US 103765901.5y
Feb 13, 2028method-of-use (U-2608)US 103765901.5y
Feb 13, 2028formulationUS 110138091.5y
Feb 13, 2028formulationUS 110138091.5y
Feb 13, 2028method-of-use (U-3135)US 117124751.5y
Feb 13, 2028method-of-use (U-3135)US 117124751.5y
Feb 13, 2028formulationUS 91801971.5y
Feb 13, 2028formulationUS 91801971.5y
Feb 13, 2028method-of-use (U-543)US 91864131.5y
Feb 13, 2028method-of-use (U-543)US 91864131.5y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 82217781.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 12, 2027formulationUS 87413271.2y
Nov 5, 2026formulationUS 1111009377d
Nov 5, 2026formulationUS 1111009377d
Sep 26, 2026method-of-use (U-2363)US 1005855437d
Sep 26, 2026method-of-use (U-2363)US 1005855437d
Sep 26, 2026formulationUS 959740237d
Sep 26, 2026formulationUS 959740237d
Jun 26, 2026formulationUS 10406160
Jun 26, 2026formulationUS 10406160

FDA exclusivities (12)

Mar 29, 2027NPNP221d
Mar 29, 2027NPNP221d
May 12, 2026CGTCGT
May 9, 2026CGTCGT
May 9, 2026CGTCGT
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP
Apr 28, 2026NPNP

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

risperidone ODT

🐶 often sniffed alongside

indications

all catalysts(0)

Trials studying risperidone ODT

Patent cliff

patents (110)

FDA exclusivities (12)

News(0)

Report a data issue

comments(0)

risperidone ODT

🐶 often sniffed alongside

indications

all catalysts(0)

Trials studying risperidone ODT

Patent cliff

patents (110)

FDA exclusivities (12)

News(0)

Report a data issue

comments(0)